Quetiapine fumarate XR
Closed Pre-Solicitation Posted
- Solicitation number
- SPE2D2-18-R-0016
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Quetiapine Fumarate Extended Release (XR) Tablets in various dosages. The contract will establish a national supply source for the Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. The projected solicitation date is December 2017.
Products and Services:
- Quetiapine Fumarate Extended Release (XR) Tablets 50MG
- Quetiapine Fumarate Extended Release (XR) Tablets 150MG
- Quetiapine Fumarate Extended Release (XR) Tablets 200MG
- Quetiapine Fumarate Extended Release (XR) Tablets 300MG
- Quetiapine Fumarate Extended Release (XR) Tablets 400MG
Notice text
4 versions
Update #4 · Latest ·
Modification SPE2D219-D-0062 P00007 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D219-D-0062 P00006 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Invocation of Option Year 4 Modification P00005 SPE2D2-19-D-0062 effective October 18, 2022 through October 17, 2023.
Invocation of Option Year 3 Modification P00004 SPE2D2-19-D-0062 effective October 18, 2021 through October 17, 2022.
QUETIAPINE FUMARATE XR
Update #3 ·
Invocation of Option Year 3 Modification P00004 SPE2D2-19-D-0062 effective October 18, 2021 through October 17, 2022.
QUETIAPINE FUMARATE XR
Update #2 ·
QUETIAPINE FUMARATE XR
Update #1 ·
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Quetiapine Fumarate Extended Release (XR) Tablets. Procurement details follow.
Quetiapine Fumarate (XR) Tablets 50MG, 150MG, 200MG, 300MG, and 400MG in 60 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Bureau of Prisons, Indian Health Service and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and FEDBIZOPS at https://www.fbo.gov. Interested parties should contact Catherine Gilbert (215)737-4778 catherine.gilbert@dla.mil for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is December of 2017. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
Files
Show all 13
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| 6505--Sacubitril/Valsartan Tablets (VA-27-00014055) | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity